Efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma

Bachkheti, Nisha; Chalia, Dharamvir; Sehgal, Vijay Kumar; Walia, Sachin

doi:10.5455/2319-2003.ijbcp20141233

Cited by 2 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 The minimum IOP readings were also significantly lower in the travoprost group than timolol group (-1.3 mm Hg; P<0.0001) and latanoprost group (-0.3mm Hg; < 0.001) which was compared to other study. 5,6 The maximum IOP readings were also significantly lower in the travoprost group as compared to timolol (-1.5 mm Hg; P<0.0001) and latanoprost group (-0.3 mm Hg. ; P< 0.02).…”

Section: Discussionmentioning

confidence: 92%

Travoprost versus latanoprost or timolol in primary open angle glaucoma- Efficacy and safety profile

Ranjan

Sugyani

Prasad³

2021

IJOOO

View full text Add to dashboard Cite

Glaucoma is progressive optical neuropathy which is challenging to treat despite advances in medical and interventional mode of treatments. Primary open angle glaucoma(POAG) is generally associated with diabetes mellitus and hypertension. Any ocular topical pharmacological agent which is to be used in POAG to maintain intraocular pressure have to be very efficacious with good safety profile. We conducted a study comparing travoprost with latanoprost and timolol as single therapeutic agent having favorable outcome.Seventy five patients were included in the study for a period of two years. After ethical clearance, patients were randomly allocated to three groups of treatment arm having 25 patients in each group. IOP was noted at 8 A.M, 10 A.M, 4 P.M on two eligibility visits for the same eye. Data collected included demographic data, blood pressure, visual acuity, ocular hyperaemia, Slit lamp finding, IOP & fundus examination. Travoprost treated patients had minimum IOP significantly lower at all visits than those using timolol (p<0.0001) and latanoprost (p<0.004). Also, Travoprost treated patient had maximum IOP records significantly lower at all visits than those using timolol (p<0.0001) and those using latanoprost (p<0.02). No significant difference was found between travoprost and latanoprost treated patients (p<0.25) while patients treated with timolol had on average a higher IOP variance (p<0.004) suggesting a lower peak control during the day. TRAVOPROST 0.004% once daily or in combination with other agents is the most effective and safest topical agents for patients of primary open angle glaucoma with the best safety profile.

show abstract

Section: Discussionmentioning

confidence: 92%

Travoprost versus latanoprost or timolol in primary open angle glaucoma- Efficacy and safety profile

Ranjan

Sugyani

Prasad³

2021

IJOOO

View full text Add to dashboard Cite

show abstract

“…Another study 26 comparing the efficacy and side effects of travoprost and tafluprost reported that travoprost produced a lower diurnal IOP than tafluprost. However, the aforementioned study has been conducted on an older age group and on a different race (Indian versus Egyptian) as compared to our study.…”

Section: Discussionmentioning

confidence: 99%

“…This observation agrees with previous studies that compared different PGAs and concluded that all drugs have similar profiles of side effects that could be related to either the preservatives or the drug molecule itself. 9,10,26,[35][36][37] However, latanoprost has been shown to have a significantly better tolerability compared to travoprost in some studies. 38,39 Also, a recent study reported that adverse reactions and conjunctival hyperemia were significantly evident with bimatoprost and travoprost as compared to latanoprost and tafluprost.…”

Section: Discussionmentioning

confidence: 99%

Comparison between Latanoprost, Travoprost, and Tafluprost in reducing intraocular pressure fluctuations in patients with glaucoma

Faseeh

Allam

Shalash

et al. 2021

European Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose: To compare the efficacies of latanoprost 0.005%, travoprost 0.004%, and tafluprost 0.0015% in reducing diurnal intraocular pressure (IOP) fluctuations in patients with newly diagnosed primary open-angle glaucoma (POAG). Methods: In this prospective randomized clinical trial, 60 patients who were newly diagnosed with POAG were divided into three equal groups. Patients were examined at presentation and at second and sixth weeks. Diurnal phasing of IOP was conducted using a calibrated Goldmann applanation tonometer. IOP measurements were recorded from 8:00 am to 9:00 am, from 3:00 pm to 4:00 pm, and from 7:00 pm to 8:00 pm. Results: The study groups were distributed similarly in terms of age and gender ( p-values: 0.76) and the participants had a mean age of 52.98 ± 13.43 years. The IOP at the day of inclusion was not statistically significant among the three groups ( p-values 0.27, 0.51, and 0.64 at 8 am, 2 pm, and 8 pm, respectively). Similar nonsignificant differences were noticed on the follow-up visits. However, the tafluprost group showed a significant reduction in IOP on the follow-up visit at the second week at 8 pm (30.5% reduction, p-value: 0.03). All three drugs showed a comparable and significant reduction in IOP and IOP fluctuations. The pattern of side effects was similar in all the groups. Conclusion: Latanoprost, travoprost, and tafluprost show a similar effectiveness in reducing the mean IOP and the diurnal IOP fluctuation in POAG. Importantly, the three drugs have comparable tolerability with insignificant differences regarding the pattern of their side effects.

show abstract

Efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma

Cited by 2 publications

References 14 publications

Travoprost versus latanoprost or timolol in primary open angle glaucoma- Efficacy and safety profile

Travoprost versus latanoprost or timolol in primary open angle glaucoma- Efficacy and safety profile

Comparison between Latanoprost, Travoprost, and Tafluprost in reducing intraocular pressure fluctuations in patients with glaucoma

Contact Info

Product

Resources

About